TY  - BOOK
AU  - Serena Martinelli
AB  - A gain-of-function mutation in Janus kinase 2 (JAK2V617F) is at the basis of the majority of chronic myeloproliferative neoplasms (MPN). Enhanced activation of other downstream pathways including the PI3K/mTOR pathway has been documented as well. In this study we evaluated the effects of JAK1/2 inhibitors, alone and in combination with mTOR, with a dual mTOR/PI3K inhibitor and with a pan PI3K inhibitor in in-vitro and in-vivo MPN models. Our findings of strong synergy between the JAK2 inhibitors and mTOR/PI3K inhibitor suggested that we might be able to administer these drugs at lower concentrations than when the drugs are used individually. This provides a framework for combination trials using compounds in patients with myeloproliferative neoplasms
DO  - 10.36253/978-88-6453-565-4
ID  - OAPEN ID: 49617
L1  - https://www.fupress.com/redir.ashx?RetUrl=3501_14477.pdf
LK  - https://directory.doabooks.org/handle/20.500.12854/60210
PB  - Firenze University Press
PY  - 2017
SN  - 9788864535654
TI  - Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasmsnull
ER  - 
